Analyst Expectations for Intra-Cellular Therapies's Future
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received positive analyst ratings in the last quarter, with an average 12-month price target of $75.0, up 4.17% from the previous target of $72.00.
June 05, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received positive analyst ratings, with an average 12-month price target of $75.0, up 4.17% from the previous target.
Intra-Cellular Therapies has received positive analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target has increased by 4.17% from the previous target, indicating a positive outlook for the stock. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100